Mybacs is described in the article as operating in biotech, health services and pharmaceutical sectors. On 22 October 2023 the company completed a €5.6 million equity financing, reported at roughly $5.99 million. The round listed participation from NaturalX Health Ventures, Wenvest Capital, SevenVentures, Global Founders Capital (GFC), Joyance Partners and G‑Fund. Coverage of the transaction in the cited text focuses on the financing amount and investor roster rather than product detail or operating metrics. The financing represents a capital injection from a mix of investment groups named in the announcement. Mybacs develops highly-dosed synbiotic dietary supplements composed of selected bacterial cultures, prebiotics, vitamins and minerals, tailored to specific customer needs and applications. The company launched Travelbacs in 2018 and later expanded its portfolio with Dailybacs, a subscription synbiotic for daily use for women, men and children. After a successful first financing in August 2019, Mybacs has completed a Seed II round to continue its growth. Participants in the new round include existing investor Global Founders Capital, returning business angels, and San Francisco–based Joyance Partners as the first international investor. The funds will be used to grow the team, develop personalized products and build a dedicated tech platform. Mybacs plans to hire specialists in technology and data and to develop a platform for symptomatic and intelligent data analysis to drive further product personalization and development. mybacs is a B2C biotech startup that develops personalized synbiotic products targeting the human gut microbiome for intestinal health. In February 2019 the company launched the world’s first regionally adapted synbiotics for prevention of travelers' diarrhea, offering 5-day capsule treatments tailored to different geographic pathogenic profiles. Products are available for Africa & the Middle East, Asia, Europe & North America, and Latin America. In the first six months after launch the startup grew greatly and currently sells through its own online shop (mybacs.co), Amazon, BRACK.CH, numerous German and Swiss pharmacies, and plans to sell through airlines. The newly closed seed financing will be used to launch another product line, expand personnel, and increase sales and marketing activities. Long-term plans include expanding the gastrointestinal health product portfolio, introducing a daily-use subscription product line in October, and offering an app to track users' health progress.

Total raised

$6M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2023